Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

534
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
534
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

367
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
367
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

304
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
304
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

355
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
355
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

402
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
402
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

176
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
176

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Gut-lung axis from a gastroenterological perspective].

MMW Fortschritte der Medizin·2025
Same author

[Fecal Microbiota Transfer (FMT) in Germany - Status and Perspective].

Zeitschrift fur Gastroenterologie·2023
Same author

[How does COVID-19 affect intestinal microbiota?]

MMW Fortschritte der Medizin·2021
Same author

Food Intolerance of Unknown Origin: Caused by Mucosal Inflammation? A Pilot Study.

Clinical and translational gastroenterology·2021
Same author

Severe acute respiratory syndrome coronavirus 2 pneumonia and pulmonary embolism in a 66-year-old woman.

Polish archives of internal medicine·2020
Same author

[A gastrointestinal overview of COVID-19].

MMW Fortschritte der Medizin·2020

Related Experiment Video

Updated: Sep 4, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K

[Gut microbiota and chronic inflammatory bowel disease].

Peter C Konturek1

  • 1ChA/Klinik für Innere Med. II/Saalfeld, Thüringen-Kliniken "Georgius Agricola" GmbH, Rainweg 68, 7318, Saalfeld, Deutschland. pkonturek@web.de.

MMW Fortschritte Der Medizin
|July 13, 2022
PubMed
Summary
This summary is machine-generated.

Intestinal dysbiosis, an imbalance in gut bacteria, is linked to inflammatory bowel disease (IBD) development and affects treatment efficacy. Understanding the gut microbiome is key to developing new therapies for IBD.

Keywords:
Intestinal microbiomebiologicschronic inflammatory bowel diseasedysbiosisperson-oriented therapy

More Related Videos

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.8K

Related Experiment Videos

Last Updated: Sep 4, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.2K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.8K

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Intestinal dysbiosis is a key factor in chronic inflammatory bowel disease (IBD) pathogenesis.
  • Gut microbiota interacts with host genetics, immunity, and environmental factors in IBD.
  • Dysbiosis impacts other organs via the gut-brain axis and influences anti-inflammatory therapy effectiveness.

Purpose of the Study:

  • To review the role of gut microbiota in IBD pathogenesis.
  • To explore microbiome-based therapeutic strategies for IBD.
  • To highlight the need for understanding host-microbiome interactions for effective IBD treatment.

Main Methods:

  • Literature review on gut microbiota and IBD.
  • Analysis of factors influencing IBD development and treatment.
  • Synthesis of current microbiome-based therapeutic approaches.

Main Results:

  • Gut dysbiosis is implicated in IBD development through complex interactions.
  • Microbiome composition significantly affects anti-inflammatory treatment outcomes.
  • Various microbiome-targeted interventions exist, including diet, probiotics, and FMT.

Conclusions:

  • Further research into host-microbiome-metabolite interactions is crucial for advancing IBD therapy.
  • Targeting the gut microbiome offers promising avenues for IBD management.
  • A comprehensive understanding of the gut ecosystem is essential for personalized IBD treatment.